Grant: Collaborative Research and Development Grants
McGill University
$75,022.00
Further development of our Drug Discovery Platform FORECASTER and its application to the design, synthesis and biological evaluation of prolyl oligopeptidase Inhibitors
EF 2010-11
Résumé
Prolyl Oligopeptidase (POP) inhibition is a highly promising strategy for the treatment of Alzheimer's disease and POP inhibitors as drug candidates are to be developed. Moitessier and co-workers have recently reported a potent, permeant and highly selective POP inhibitor. However, its stability and pharmacokinetic profile need to be improved. A large number of drug discovery and development projects fail at the late development stages due to poor pharmacokinetic profiles. Integrating the evaluation of absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) of potential candidate drugs early in the drug discovery process is expected to significantly reduce this failure rate. IIi this context, predicting the ADME-Tox profile using computational methods has been seen as a high-throughput and inexpensive option that could complement low to medium throughput in vitro or in vivo assays. Moitessier and co-workers have developed a sophisticated platform of programs (FORECASTER) which performs virtual screening, docking and more (www.fitted.ca). In this research, we plan to combine our complementary expertise in organic synthesis, medicinal chemistry, metabolism and software development to 1. develop accurate in silico methods that predict the cytochrome P450-mediated metabolism and P450 inhibition and implement them in our platform FORECASTER; 2. apply this suite of programs to the development of improved POP inhibitors.
This research will provide a computational alternative to the low throughput metabolism assays for the Canadian Pharmaceutical Industry. It will also identify novel molecules as potential treatment for Alzheimer's disease based on this target. The collaboration with AstraZeneca will provide the PI with the knowledge in metabolism essential to the development of an accurate computational tool and enable realistic application of the developed platform (FORECASTER) to medicinal chemistry as carried out in the pharmaceutical industry. This multidisciplinary program will also enable the training of students and fellows who will acquire skills in the highly-valued areas of computer-aided drug design, multistep organic synthesis, and medicinal chemistry.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
387267-2009
Name nom
Moitessier, Nicolas
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2009
Award amount
75022
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
2
Application title
Further development of our Drug Discovery Platform FORECASTER and its application to the design, synthesis and biological evaluation of prolyl oligopeptidase Inhibitors
Keyword
NSERC
Application summary
Prolyl Oligopeptidase (POP) inhibition is a highly promising strategy for the treatment of Alzheimer's disease and POP inhibitors as drug candidates are to be developed. Moitessier and co-workers have recently reported a potent, permeant and highly selective POP inhibitor. However, its stability and pharmacokinetic profile need to be improved. A large number of drug discovery and development projects fail at the late development stages due to poor pharmacokinetic profiles. Integrating the evaluation of absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) of potential candidate drugs early in the drug discovery process is expected to significantly reduce this failure rate. IIi this context, predicting the ADME-Tox profile using computational methods has been seen as a high-throughput and inexpensive option that could complement low to medium throughput in vitro or in vivo assays. Moitessier and co-workers have developed a sophisticated platform of programs (FORECASTER) which performs virtual screening, docking and more (www.fitted.ca). In this research, we plan to combine our complementary expertise in organic synthesis, medicinal chemistry, metabolism and software development to 1. develop accurate in silico methods that predict the cytochrome P450-mediated metabolism and P450 inhibition and implement them in our platform FORECASTER; 2. apply this suite of programs to the development of improved POP inhibitors.
This research will provide a computational alternative to the low throughput metabolism assays for the Canadian Pharmaceutical Industry. It will also identify novel molecules as potential treatment for Alzheimer's disease based on this target. The collaboration with AstraZeneca will provide the PI with the knowledge in metabolism essential to the development of an accurate computational tool and enable realistic application of the developed platform (FORECASTER) to medicinal chemistry as carried out in the pharmaceutical industry. This multidisciplinary program will also enable the training of students and fellows who will acquire skills in the highly-valued areas of computer-aided drug design, multistep organic synthesis, and medicinal chemistry.